Sarepta Therapeutics, a company facing regulatory scrutiny regarding its gene therapy for Duchenne muscular dystrophy, has reportedly hired a lobbying firm with ties to the Trump administration following the tragic death of a teenage patient who had been treated with their drug.
The decision to enlist the services of a Trump-connected lobbying firm comes at a critical time for Sarepta Therapeutics, as they navigate the fallout from the teenager’s passing and seek to address any potential regulatory concerns surrounding their gene therapy treatment.
The lobbying disclosure reports indicate that Sarepta Therapeutics is taking proactive steps to protect its interests and advocate for its gene therapy in the face of increased scrutiny and public scrutiny.
The hiring of a lobbying firm with ties to the Trump administration suggests that Sarepta Therapeutics is leveraging political connections to navigate the complex regulatory landscape and ensure that their gene therapy for Duchenne muscular dystrophy receives the necessary support and approval from regulatory authorities.
It remains to be seen how the involvement of a Trump-connected lobbying firm will impact Sarepta Therapeutics’ efforts to address regulatory concerns and secure approval for their gene therapy treatment. However, the company’s decision to enlist the services of a lobbying firm underscores the high stakes involved in the development and approval of innovative gene therapies for rare and life-threatening diseases.
As Sarepta Therapeutics continues to navigate the regulatory landscape and advocate for their gene therapy for Duchenne muscular dystrophy, it is clear that the company is taking proactive steps to protect their interests and ensure the success of their groundbreaking treatment.
